X

Trial Profile

Aggressive lipid-lowering treatment approaches for vulnerable plaque in coronary artery with rosuvastatin. -Assessment using angioscopy and intravascular ultrasound -

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 13 May 2016

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rosuvastatin (Primary)
Indications Atherosclerosis; Coronary artery disease; Hypercholesterolaemia
Focus Therapeutic Use
Acronyms ALTAIR

Most Recent Events

28 Jan 2016 As per an advice from the Independent Data Monitoring Committee after an assessment at week 48, this trial was terminated in April 2013, according to an article published in the The American Journal of Cardiology.
28 Jan 2016 Results published in the American Journal of Cardiology
20 Nov 2013 Results presented at the 86th Annual Scientific Sessions of the American Heart Association.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com